Literature DB >> 24696184

Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.

Byunghee Yoo1, Marytheresa A Ifediba, Subrata Ghosh, Zdravka Medarova, Anna Moore.   

Abstract

PURPOSE: Tumor resistance to chemotherapeutic drugs is one of the major obstacles in the treatment of glioblastoma multiforme (GBM). In this study, we attempted to modulate tumor response to chemotherapy by combination treatment that included experimental (small interference RNA (siRNA), chlorotoxin) and conventional (temozolomide, TMZ) therapeutics. PROCEDURES: siRNA therapy was used to silence O(6)-methylguanine methyltransferase (MGMT), a key factor in brain tumor resistance to TMZ. For targeting of tumor cells, we used chlorotoxin (CTX), a peptide with antitumoral properties. siRNA and CTX were conjugated to iron oxide nanoparticles (NP) that served as the drug carrier and allowed the means to monitor the changes in tumor volume by magnetic resonance imaging (MRI).
RESULTS: Theranostic nanoparticles (termed CTX-NP-siMGMT) were internalized by T98G glioblastoma cells in vitro leading to enhancement of TMZ toxicity. Combination treatment of mice bearing orthotopic tumors with CTX-NP-siMGMT and TMZ led to significant retardation of tumor growth, which was monitored by MRI.
CONCLUSIONS: While our results demonstrate that siRNA delivery by targeted nanoparticles resulted in modulating tumor response to chemotherapy in GBM, they also point to a significant contribution of CTX to tumor cell death.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696184     DOI: 10.1007/s11307-014-0734-3

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  49 in total

1.  Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles.

Authors:  Conroy Sun; Chen Fang; Zachary Stephen; Omid Veiseh; Stacey Hansen; Donghoon Lee; Richard G Ellenbogen; Jim Olson; Miqin Zhang
Journal:  Nanomedicine (Lond)       Date:  2008-08       Impact factor: 5.307

Review 2.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Authors:  Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi
Journal:  Nat Rev Neurol       Date:  2009-12-08       Impact factor: 42.937

3.  Gene expression profiling predicts response to temozolomide in malignant gliomas.

Authors:  Atsuo Yoshino; Akiyoshi Ogino; Kazunari Yachi; Takashi Ohta; Takao Fukushima; Takao Watanabe; Yoichi Katayama; Yutaka Okamoto; Norio Naruse; Emiko Sano; Kouhei Tsumoto
Journal:  Int J Oncol       Date:  2010-06       Impact factor: 5.650

4.  O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow.

Authors:  N Chinnasamy; J A Rafferty; I Hickson; J Ashby; H Tinwell; G P Margison; T M Dexter; L J Fairbairn
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

5.  Image-guided breast tumor therapy using a small interfering RNA nanodrug.

Authors:  Mohanraja Kumar; Mehmet Yigit; Guangping Dai; Anna Moore; Zdravka Medarova
Journal:  Cancer Res       Date:  2010-08-11       Impact factor: 12.701

6.  Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects.

Authors:  Kamala Kesavan; Judson Ratliff; Eric W Johnson; William Dahlberg; John M Asara; Preeti Misra; John V Frangioni; Douglas B Jacoby
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

7.  CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.

Authors:  Maria F Paz; Ricard Yaya-Tur; Iñigo Rojas-Marcos; Gaspar Reynes; Marina Pollan; Lucinda Aguirre-Cruz; Jose Luis García-Lopez; Jose Piquer; María-Jose Safont; Carmen Balaña; Montserrat Sanchez-Cespedes; Mercedes García-Villanueva; Leoncio Arribas; Manel Esteller
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

Review 8.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

9.  Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging.

Authors:  Derek W Bartlett; Mark E Davis
Journal:  Nucleic Acids Res       Date:  2006-01-12       Impact factor: 16.971

10.  A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection.

Authors:  Ping Wang; Mehmet V Yigit; Chongzhao Ran; Alana Ross; Lingling Wei; Guangping Dai; Zdravka Medarova; Anna Moore
Journal:  Diabetes       Date:  2012-08-24       Impact factor: 9.461

View more
  8 in total

1.  Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.

Authors:  Byunghee Yoo; Amol Kavishwar; Alana Ross; Ping Wang; Doris P Tabassum; Kornelia Polyak; Natalia Barteneva; Victoria Petkova; Pamela Pantazopoulos; Aseda Tena; Anna Moore; Zdravka Medarova
Journal:  Cancer Res       Date:  2015-09-10       Impact factor: 12.701

2.  Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.

Authors:  Hui Shi; Shuo Sun; Haoyue Xu; Zongren Zhao; Zhengzhong Han; Jun Jia; Dongmei Wu; Jun Lu; Hongmei Liu; Rutong Yu
Journal:  Int J Nanomedicine       Date:  2020-05-12

Review 3.  Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology.

Authors:  Andrew M Hersh; Safwan Alomari; Betty M Tyler
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

4.  PEI-Coated Fe₃O₄ Nanoparticles Enable Efficient Delivery of Therapeutic siRNA Targeting REST into Glioblastoma Cells.

Authors:  Rui Wang; Volkan Degirmenci; Hongchuan Xin; Ying Li; Liping Wang; Jiayu Chen; Xiaoyu Hu; Dianbao Zhang
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

5.  Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells.

Authors:  Zdravka Medarova; Pamela Pantazopoulos; Byunghee Yoo
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

Review 6.  Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme.

Authors:  L Nam; C Coll; L C S Erthal; C de la Torre; D Serrano; R Martínez-Máñez; M J Santos-Martínez; E Ruiz-Hernández
Journal:  Materials (Basel)       Date:  2018-05-11       Impact factor: 3.623

7.  Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma.

Authors:  Masaki Yoshioka; Tomoo Matsutani; Ayaka Hara; Seiichiro Hirono; Takaki Hiwasa; Masaki Takiguchi; Yasuo Iwadate
Journal:  Oncotarget       Date:  2018-06-12

Review 8.  Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?

Authors:  Claire Gazaille; Marion Sicot; Patrick Saulnier; Joël Eyer; Guillaume Bastiat
Journal:  Front Med Technol       Date:  2021-11-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.